Orally Disintegrating Antipsychotics May Promote Compliance and Adherence in Patients With Schizophrenia

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Kane et al., in their recent (January 2005) CME activity"Optimizing Pharmacotherapy to Maximize Outcome inSchizophrenia,"¹ recommend using a long-acting depot injectionin patients who fail to adhere to antipsychotic treatment.While depot medications ensure compliance, they may not fostercertain aspects of the doctor-patient relationship, and evenwith depot medication, about 25% of patients stop keepingscheduled appointments and no longer receive depot injectionswithin 1 year after starting treatment.² Furthermore, depotmedications may be associated with an increased risk for prolongedside effects.³‘ ‹